Journal — News
Regulatory motion, FDA updates, and editorial briefs.
Jul 31, 2026 · 4 min
A joint government warning covers iDEXIS semaglutide, tirzepatide, and mixed products—and threatens disciplinary action for continued prescribing, dispensing, or stockholding.
@peptidedesk
Jul 31, 2026 · 4 min
The official catalog lists injectable semaglutide as item 325 and takes effect in September, placing a second GLP-1 medicine alongside liraglutide without creating a new obesity indication.
@peptidedesk
Jul 31, 2026 · 5 min
A prescription analysis associated the March 2024 cardiovascular indication and coverage shift with 592,624 additional Wegovy fills by September—but estimated Part D uptake remained below 1% of eligible beneficiaries.
@peptidedesk
Jul 29, 2026 · 4 min
A network meta-analysis ranked weekly semaglutide highest for estimated weight reduction, but sparse and largely indirect evidence makes that ranking uncertain.
@peptidedesk
Jul 29, 2026 · 4 min
A large observational analysis linked higher attained doses with fewer later cardiovascular events, while the amount of weight lost showed a weaker relationship.
@peptidedesk
Jul 29, 2026 · 4 min
A post hoc analysis found slower movement across several epigenetic clocks in adults with HIV-associated lipohypertrophy—but it did not test lifespan or prove an anti-aging effect.
@peptidedesk
Jul 28, 2026 · 4 min
A recall triggered by a Dr. Reddy's notice underscores persistent quality and supply-chain friction across the global GLP-1 market.
@peptidedesk
Jul 28, 2026 · 4 min
Novo Nordisk moves to evaluate a long-acting semaglutide implant, signaling the next phase of delivery innovation in the GLP-1 space.
@peptidedesk
Jul 22, 2026 · 6 min
A BMJ network meta-analysis finds meaningful variation across obesity medicines on weight loss, quality-of-life thresholds, and cardiovascular endpoints—complicating class-level claims.
@peptidedesk
Jul 22, 2026 · 6 min
Syndicated safety questions lump approved drugs, compounded preparations, and unapproved online chemicals into one word. The evidence requires separating them.
@peptidedesk
Jul 22, 2026 · 5 min
How a single brand name became shorthand for an entire therapeutic class—and the legal exposure that follows.
@peptidedesk
Jul 22, 2026 · 4 min
A Phase 1 program characterizes orforglipron's interaction profile with common enzyme and transporter pathways, but the scope is narrower than some headlines suggest.
@peptidedesk
Jul 22, 2026 · 5 min
A Canadian modeling study projects that generic semaglutide could improve affordability and access for diabetes care, but projected outcomes remain distinct from observed post-launch results.
@peptidedesk
Jul 22, 2026 · 4 min
A new study documents rapid growth in US GLP-1 receptor agonist utilization and total payments, driven primarily by semaglutide. The payment measure captures insurer and patient spending but cannot be read as out-of-pocket cost alone.
@peptidedesk
Jul 22, 2026 · 4 min
A target-trial emulation comparing GLP-1 receptor agonists with oral antidiabetic agents found no significant difference in rates of insulin discontinuation among patients with type 2 diabetes.
@peptidedesk
Jul 22, 2026 · 7 min
A close look at the SELECT trial: who was studied, what endpoints moved, and why relative risk reductions deserve careful interpretation.
@peptidedesk
Jul 22, 2026 · 4 min
A target-trial emulation reports a difference in diabetes outcomes between semaglutide and liraglutide users. Here is what the method can and cannot tell us.
@peptidedesk
Jul 22, 2026 · 6 min
As the national GLP-1 supply stabilizes, FDA enforcement policy is shifting. Here is what clinicians worry about, what compounding rules actually permit, and what patients should understand about approval, formulation, and dosing.
@peptidedesk
Jul 22, 2026 · 7 min
A guide to the three most discussed incretin therapies, the available head-to-head evidence, and why cross-trial weight-loss rankings can mislead.
@peptidedesk
Jul 22, 2026 · 6 min
An NPR explainer frames a widening gap between approved peptide medicines, compounded preparations, and unapproved wellness products. Here is why the distinctions matter.
@peptidedesk
Jul 22, 2026 · 5 min
An evidence-first look at online melanotan products, why the nickname obscures more than it reveals, and the regulatory gap separating unapproved tanning peptides from approved melanocortin medicines.
@peptidedesk
Jul 22, 2026 · 5 min
Retrospective work on obesity phenotypes and the hungry-gut concept offers a framework for predicting differential response to GLP-1-based therapy, but prospective validation remains outstanding.
@peptidedesk
Jul 22, 2026 · 6 min
The TGA targets unapproved online peptide supply, University of Queensland researchers flag injectable product risks, and Sport Integrity Australia warns athletes that many peptides carry anti-doping liability.
@peptidedesk
Jul 21, 2026 · 5 min
Exposure reports are climbing as more patients use GLP-1 receptor agonists. The data reveal recurring dosing-error patterns, but exposure calls are not confirmed poisonings, and the source of product is not always compounded.
@peptidedesk
Jul 21, 2026 · 6 min
A new Johns Hopkins analysis reports no statistically significant association between semaglutide and degenerative eye disease in adults with type 2 diabetes, but the findings do not rule out all ophthalmic risks.
@peptidedesk
Jul 21, 2026 · 4 min
Novo alleges Lilly's comparative ads mislead on dosing and efficacy. Lilly says it stands behind its advertising and will defend the lawsuit.
@peptidedesk
Jul 21, 2026 · 4 min
A GLP-1 receptor agonist cleared for metabolic liver disease highlights the shifting boundary between obesity care and hepatology—but the public record is still thin.
@peptidedesk
Jul 21, 2026 · 6 min
A subgroup analysis of the SUMMIT trial suggests tirzepatide's benefit in obesity-related HFpEF holds across sexes, but the limits of subgroup data deserve as much attention as the headline.
@peptidedesk
Jul 21, 2026 · 4 min
The European Commission has approved an oral semaglutide formulation, but country-level launches, pricing, and reimbursement remain unresolved.
@peptidedesk
Jul 21, 2026 · 5 min
The FDA's Pharmacy Compounding Advisory Committee meets July 23-24, 2026, to review seven peptide substances. Here is what the panel can and cannot do.
@peptidedesk
Jul 14, 2026 · 4 min
A Nature analysis suggests cardioprotective effects track the dose patients actually sustain rather than the pounds they drop, with implications for GLP-1 dosing strategies.
@peptidedesk
Jul 14, 2026 · 4 min
Sandoz's accepted FDA applications for generic tirzepatide signal potential competition in the GLP-1 market, though a broader biosimilar development gap persists.
@peptidedesk
Jul 14, 2026 · 4 min
Cleveland Clinic publishes an educational overview comparing the two dominant GLP-1 receptor agonists, breaking down differences in mechanism, efficacy, and clinical context for patients and researchers tracking metabolic peptide developments.
@peptidedesk
Jul 14, 2026 · 4 min
A retrospective Cureus study adds real-world data on pairing a GLP-1 receptor agonist with an SGLT2 inhibitor for type 2 diabetes.
@peptidedesk
Jul 14, 2026 · 4 min
A reported Phase 3 readout for a GLP-3 receptor agonist hints at a next-generation metabolic peptide class. The data is preliminary and sourced through a single news aggregator—here is what is actually known.
@peptidedesk
Jul 14, 2026 · 4 min
A Discover Magazine report ties a spike in poison control calls to two avoidable semaglutide measurement mistakes, underscoring safety risks as compounded and research-grade GLP-1 products circulate widely.
@peptidedesk
Jul 14, 2026 · 4 min
The UK's General Pharmaceutical Council warns consumers about counterfeit online pharmacies as demand for GLP-1 weight-loss treatments surges following the introduction of oral semaglutide.
@peptidedesk
Jul 13, 2026 · 4 min
New research hints that tirzepatide's weight-loss effects may extend beyond appetite suppression, potentially altering how the body expends energy.
@peptidedesk
Jul 13, 2026 · 4 min
Singapore's health authority has updated the Wegovy label to include a higher dose of semaglutide, citing STEP UP trial evidence. Here's what the regulatory move signals for GLP-1 peptide access.
@peptidedesk
Jul 13, 2026 · 4 min
A preview of anticipated obesity drug data at ADA 2026, covering next-generation peptide therapeutics retatrutide, CagriSema, and oral GLP-1 candidates expected to shape the competitive GLP-1 landscape.
@peptidedesk
Jul 10, 2026 · 4 min
A quality setback at Dr. Reddy's Laboratories pushes back the company's semaglutide supply timeline and rattles investors, with potential implications for the generic GLP-1 competitive landscape.
@peptidedesk
Jul 9, 2026 · 4 min
A Washington Post report spotlights the surging underground interest in retatrutide, an experimental triple-agonist peptide being used off-label for weight loss before it clears regulatory hurdles.
@peptidedesk
Jul 9, 2026 · 4 min
Novo Nordisk is backing Vivani Medical to develop a sustained-release semaglutide implant, signaling fresh industry appetite for depot delivery of GLP-1 therapeutics beyond weekly injections.
@peptidedesk
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.